The BARDA grant is not like cash backing. It has to be spent getting LANI through Phase3 trials in the USA. Whilst this is reasonably low risk (given the success of Inavir in Japan), it's all in the mid-term and will be several years before we have sales revenue, and that in turn will be as predictable as the flu season etc. It's all about risk and whilst we are much better positioned now than a month ago, I won't be topping up over $1.20.
BTA Price at posting:
$1.35 Sentiment: LT Buy Disclosure: Held
